Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: A phase I dose escalation trial

Onkologie

Volumn 30, Issue 1-2, 2007, Pages 29-34

  Al Batran, S E ^a   Kerber, A ^a   Atmaca, A ^a   Dechow, C ^a   Reitsamer, E ^a   Schmidt, S ^a   Kolassa, Y ^a   Neumann, A ^a   Weidmann, E ^a   Hartmann, J T ^b   Jager E ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Gastric cancer; Mitomycin C; Oxaliplatin

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; OXALIPLATIN;

ADULT; AGED; ANEMIA; APPETITE DISORDER; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HYPERSENSITIVITY; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION; LEUKEMIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; PAIN; PHASE 1 CLINICAL TRIAL; SALVAGE THERAPY; SKIN TOXICITY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; STOMACH NEOPLASMS; TERMINAL CARE; TREATMENT OUTCOME;

EID: 33846595634     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097768     Document Type: Article

References (21)

1. Janunger KG, Hafstrom L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001;40:309-326.
2. Kohne CH, Wils JA, Wilke HJ: Developments in the treatment of gastric cancer in Europe. Oncology 2000;14:22-25.
3. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej Cl: CPT-11 plus cisplatin in patients with advanced untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002;94:641-646.
4. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, François E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.
6. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658-663.
7. Al-Batran SE, Hartmann JT, Probst S, Hofheinz R, Stoehlmacher J, Schmalenberg H, Hollerbach S, Schuch G, Homann N, Jäger E: A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). ASCO Annu Meet Proc. Part I. J Clin Oncol 2006;24:LBA4016 (abstr).
8. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, Meyer J, Bunte H: Chemotherapy of gastric cancer. Cancer Treat Rev 1998;15:257-277.
9. Wilson D, Hiller L, Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005;17:81-90.
10. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK: Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003;14:383-387.
11. Di Francesco AM, Ruggiero A, Riccardi R: Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002;59:1914-1927.
12. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C: Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002;20:2031-2037.
13. Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Kohne CH, Kafer G, Kanz L, Bokemeyer C: Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 2003;89:2051-2056.
14. Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W: High-dose 5-fluorouracil/folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study. Onkologie 2002;25:255-260.
15. Rudi J, Werle S, Bergtholdt D, Hofheinz RD: Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer. Onkologie 2005;28:128-132.
16. Bleiberg H: Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 1998;77(suppl 4):1-3.
17. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A: OPTI-MOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;24:394-400.
18. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
19. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; Japan Clinical Oncology Group Study: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol 2003;21:54-59.
20. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;20:3130-3136.
21. Scheithauer W, Kornek GV, Brugger S, Ulrich-Pur H, Valencak J, Raderer M, Fiebiger W, Kovats E, Lang F, Depisch D: Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/ leucovorin-pretreated colorectal cancer. Cancer Invest 2002;20:60-68.